Continuous Glucose Monitoring: A Pilot Study

Last updated: July 31, 2025
Sponsor: Loma Linda University
Overall Status: Active - Not Recruiting

Phase

N/A

Condition

Anesthesia

Treatment

Dexcom G7® sensor placed in upper arm and positioned over deltoid

Dexcom G7® sensor placed in anterior thigh

Clinical Study ID

NCT06614127
IRB 5230596
  • Ages 18-65
  • All Genders

Study Summary

The purpose of this study is to evaluate connectivity of the FDA approved DexCom G7® continuous glucose monitor in the operating room. Continuous glucose monitors are applied to the skin and a thin sampling filament is inserted into the skin and measures blood sugar in the interstitial fluid. The DexCom G7® is used regularly outside of the operating room to monitor blood sugar, however the use of the device in the operating room environment has been limited by connectivity issues. This study will assess device connectivity at different monitoring sites.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Adults age 18 and above able to consent for themselves

  • Willingness and ability to participate in study procedures

  • Surgery length estimated 3 hours or longer

Exclusion

Exclusion Criteria:

  • Cardiothoracic surgical patients

  • Plan for intraoperative radiologic imaging

  • Patients on IV infusion of insulin prior to surgery

  • Anemia with hemoglobin less than 7

  • Patients on hydroxyurea

  • Patients with known adhesive allergies

  • Pregnant women

Study Design

Total Participants: 40
Treatment Group(s): 2
Primary Treatment: Dexcom G7® sensor placed in upper arm and positioned over deltoid
Phase:
Study Start date:
October 24, 2024
Estimated Completion Date:
October 31, 2026

Study Description

This feasibility pilot study will assess connectivity of the DexCom G7® continuous glucose monitoring device (CGM) in the operating room environment at different locations on the body. The investigators believe device connectivity is affected by use of electrocautery. The monitoring sites were selected to limit electromagnetic interference from electrocautery.

One cohort will have the CGM device placed on the deltoid and the electrodispersive pad placed on the thigh and the other cohort will have the CGM device placed on the thigh with the electrodispersive pad on the opposite thigh.

Study personnel will note when electrocautery is used throughout the surgery and observe if the DexCom G7® continues to maintain connectivity with the receiver and provides a glucose reading. Comparing the timing of electrocautery use with connectivity to the DexCom G7® receiver provides important insight to the relationship between electrocautery and device connectivity.

The CGM readings will solely be used for feasibility purposes for this study and not for determining interventions for the subjects.

Connect with a study center

  • Loma Linda University Troesch Medical Center

    Loma Linda, California 92354
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.